Maturitas
Volume 60, Issue 1 , Pages 42-49 , 20 May 2008

The menopausal hot flush—Anything new?

Received 5 December 2007 ,Revised 23 January 2008 ,Accepted 6 February 2008.

References 

  1. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39–60 yrs old. Am J Obstet Gynecol. 1993;168:772–780
  2. Beyene Y, Martin MC. Menopausal experiences and bone density of Mayan women in Yucatan, Mexico. Am J Hum Biol. 2001;13:505–511
  3. Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric. 2007;10:197–214
  4. Albery N. The menopause in Japan—konenki jigoku. Climacteric. 1999;2:160–161
  5. Anderson D, Yoshizawa T, Gollschewski S, Atogami F, Courtney M. Menopause in Australia and Japan: effects of country of residence on menopausal status and menopausal symptoms. Climacteric. 2004;7:165–174
  6. Appling S, Paez K, Allen J. Ethnicity and vasomotor symptoms in postmenopausal women. J Women's Health. 2007;16:1130–1138
  7. Crandall CJ, Crawford SL, Gold EB. Vasomotor symptom prevalence is associated with polymorphisms in sex-steroid metabolising enzymes and receptors. Am J Med. 2006;119(9 Suppl. 1):s52–s60
  8. Thurston RC, Sowers MR, Chang Y, et al. Adiposity and reporting of vasomotor symptoms among midlife women: the study of Women's Health Across the Nation. Am J Epidemiol. September 19, 2007;[E Pub ahead of print]
  9. Sievert LL, Flanagan EK. Geographical distribution of hot flash frequencies: considering climatic influences. Am J Phys Anthropol. 2005;128:437–443
  10. Voda AM. Climacteric hot flash. Maturitas. 1981;3:73–90
  11. Sturdee DW. Biological responses to the female climacteric and oestrogen–progestogen therapy. MD Thesis. University of Birmingham; 1979.
  12. Tataryan IV, Lomax P, Bajorek JG, et al. Postmenopausal hot flushes: a disorder of thermoregulation. Maturitas. 1980;2:101–107
  13. Erlik Y, Tataryan IV, Meldrum DR, et al. Association of waking episodes with menopausal hot flushes. J Am Med Assoc. 1981;245:1741–1744
  14. Freedman RR, Roehrs TA. Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance. Menopause. 2006;13:576–583
  15. Kronenberg F. Hot Flashes: epidemiology and physiology. Ann NY Acad Sci. 1990;592:52–86
  16. Molnar GW. Body temperatures during menopausal hot flashes. J Appl Physiol. 1975;38:499–503
  17. Sturdee DW, Reece BL. Thermography of menopausal hot flushes. Maturitas. 1979;1:201–205
  18. Tataryn IV, Meldrum DR, Lu KH, Frumar AM, Judd HL. LH, FSH and skin temperature during the menopausal hot flush. J Clin Endocrinol Metab. 1979;49:152–154
  19. Kronenberg F, Cote LJ, Linkie DM, Dyrenfurther I, Downey JA. Menopausal hot flashes: thermoregulatory, cardiovascular and circulating catecholamine and LH changes. Maturitas. 1984;6:31–43
  20. Sturdee DW, Wilson KA, Pipili E, Crocker AD. Physiological aspects of menopausal hot flush. Br Med J. 1978;2:79–80
  21. Silverman RW, Bajorek JG, Lomax P, Tataryn IV. Monitoring the pathophysiological correlates of postmenopausal hot flushes. Maturitas. 1981;3:39–46
  22. Freedman RR, Wasson S. Miniature hygrometric hot flash recorder. Fertil Steril. 2007;88:494–496
  23. Schoenbaum E. Animal models of postmenopausal hot flushes. In:  Lomax P,  Vessel ES editor. The Climacteric Hot Flush. Progress in Basic and Clinical Pharmacology. Karger; 1991;p. 108–118
  24. MacLennan AH, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric. 2001;4:58–74
  25. Freedman RR. Pathophysiology and treatment of hot flashes. Semin Reprod Med. 2005;23:117–125
  26. Campbell S, Breeson AJ, Kitchin Y, Fergusson IK, Biswas S. Intensive steroid and protein hormone profiles on postmenopausal women experiencing hot flushes, and a group of controls. In: Campbell S, editor. The management of the menopause and postmenopausal years. Lancaster: MTP Press Ltd.; in press. p. 63–77.
  27. Hutton JD, Jacobs HS, Murray MF, James VHT. Relationship between plasma oestrone and oestradiol and climacteric symptoms. Lancet. 1978;1:678–681
  28. Meldrum DR, Erlik Y, Lu JKH, Judd HL. Objectively recorded hot flushes in patients with pituitary insufficiency. J Clin Endocrinol Metab. 1981;52:684–687
  29. Meldrum DR, Tataryan IV, Frumar A, Gonadotrophins ME. estrogens and adrenal steroids during the menopausal hot flash. J Clin Endocrinol Metab. 1980;50:685–689
  30. Shaw RW, Kerr-Wilson RHJ, Fraser HM, et al. The effect of an intranasal LHRH agonist on gonadotrophins and hot flushes in postmenopausal women. Maturitas. 1985;7:161–167
  31. Simpkins JW, Kalra SP. Central sites of norepinephrine and LHRH interaction. Fed Proc. 1979;38:1107
  32. Berendsen HHG. The role of serotonin in hot flushes. Maturitas. 2000;36:155–164
  33. Nelson HD, Vesco KK, Haney E, et al. Non-hormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295:2057–2071
  34. Reddy SY, Warner H, Guttoso T, et al. Gabapentin, estrogen and placebo for treating hot flushes: a randomised controlled trial. Obstet Gynecol. 2006;108:4–5
  35. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flushes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005;366:818–824
  36. Unfer V, Casini M, Costabile L, et al. Endometrial effects of long-term treatment with phytoestrogens: a randomised, double-blind, placebo-controlled study. Fertil Steril. 2004;82:145–148
  37. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomised, placebo-controlled crossover trial of Black cohosh in the management of hot flashes. J Clin Oncol. 2006;24:2836–2841
  38. Levitsky J, Alli TA, Wisecorner J, Sorrell ME. Fulminate liver failure associated with the use of Black cohosh. Dig Dis Sci. 2005;50:538–539
  39. Lynch CR, Folkers ME, Hutson WR. Fulminating hepatic failure associated with the use of Black Cohosh: a case report. Liver Transplant. 2006;12:989–992
  40. Hickey M, Saunders CM, Stuckey BG. Non-hormonal treatments for menopausal symptoms. Maturitas. 2007;57:85–89
  41. Alfhaily F, Ewies AAA. Acupuncture in imaging menopausal symptoms: hope or mirage. Climacteric. 2007;10:371–380
  42. Sturdee DW, MacLennan AH. Not all placebos are equally pleasing. Climacteric. 2006;9:401–403
  43. Ernst E. Placebo, deceit and complementary/alternative medicine. Climacteric. 2007;10:85–87
  44. Grady D. Management of menopausal symptoms. N Engl J Med. 2006;355:2338–2347
  45. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with the lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75:1065–1079
  46. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric. 2007;10:120–131
  47. Bachmann GA, Schaefors M, Uddin A, Utian WH. Lowest effective transdermal 17β-estradiol dose for relief of hot flushes in postmenopausal women: a randomised controlled trial. Obstet Gynecol. 2007;110:770–779
  48. Paterson MEL. A randomised double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. Brit J Obstet Gynaecol. 1982;89:464–472
  49. Farish E, Barnes JF, O’Donoghue F, et al. The role of megestrol acetate as an alternative to conventional hormone replacement therapy. Climacteric. 2000;3:125–134
  50. Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol. 2006;24:1409–1414
  51. Freedman RR, Woodward S. Behavioural treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol. 1992;167:436–439
  52. The Endocrine society position statement. http://www.endo-society.org.
  53. Pines A, Sturdee DW, Birkhäuser MH, et al. On behalf of the Board of the International Menopause Society IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007;10:181–194
  54. Food and Drugs Administration. FDA News. FDA takes action against compounded menopause hormone therapy drugs. http://www.fda.gov/cder/pharmocomp/default.htm.

☆ Paper based on presentation given at Lisbon's IVth International Menopause Symposium, 20th October 2007.

PII: S0378-5122(08)00041-8

doi: 10.1016/j.maturitas.2008.02.006

Maturitas
Volume 60, Issue 1 , Pages 42-49 , 20 May 2008

Article Tools

* Image Usage & Resolution